Publications by authors named "L Bocket"
Background: Doravirine is the latest NNRTI to be approved for the treatment of HIV-1 and has a different resistance profile from first-generation NNRTIs. Our aim was to investigate the virological efficacy of antiretroviral treatment including doravirine in people living with HIV-1 (PLWHIV), the factors associated with virological failure (VF) and those associated with the emergence of reverse transcriptase (RT) mutations in the case of VF.
Methods: A retrospective national survey of PLWHIV who were either naive or experienced on antiretroviral treatment including doravirine was conducted.
Diagnosis of hepatitis E virus (HEV) infection relies first on detection of IgM antibodies (Ab), sometimes completed with HEV RNA detection. This study aimed to compare the performance of two automated anti-HEV IgM Ab assays. Correlation between Virclia® (Vircell) and Liaison® (Diasorin) assays was carried out on 178 routine clinical samples.
View Article and Find Full Text PDFObjectives: As many disparities in the clinical use of HIV DNA sequencing are observed, a DELPHI-type consensus was initiated in France to homogenize use, techniques and interpretation of results.
Methods: Based on a literature review and clinical experience, a steering committee (SC) of eight virologists and one infectious disease specialist formulated statements. Statements were submitted to an independent and anonymous electronic vote of virologists and HIV clinicians in France, between October 2022 and December 2022.
The ongoing outbreak of monkeypox virus (MPXV) is the largest one in historically non-endemic countries. Early reports described atypical epidemiological and clinical presentations. We investigated MPXV DNA detection in oropharyngeal samples (OPS), and compared the viral load to that in lesion samples at diagnosis in patients infected with MPXV.
View Article and Find Full Text PDFArticle Synopsis
- This study explored the effectiveness of the BNT162b2 booster vaccine on neutralizing antibodies and T cell responses in healthcare workers against the Omicron sublineages BA.1 and BA.2, before and three months after vaccination.
- Results showed that before the booster, a small percentage of participants had measurable neutralizing activity, but by three months post-booster, nearly all had developed strong antibody responses against Delta and Omicron variants, although the levels were lower for BA.1 and BA.2 than for Delta.
- Participants with recent SARS-CoV-2 infections maintained stable antibody levels, while those without infections experienced a decrease in neutralizing antibody titres over the three-month period.